Which is better, EGFR-TKI mono or combination for non-small cell lung cancer with mutated EGFR?
Transl Cancer Res
.
2019 Oct;8(6):2223-2229.
doi: 10.21037/tcr.2019.08.18.
Authors
Shigeru Tanzawa
1
,
Masashi Ishihara
1
,
Terunobu Haruyama
1
,
Ryosuke Ochiai
1
,
Takahiko Sakamoto
1
,
Takeshi Honda
1
,
Shuji Ota
1
,
Yasuko Ichikawa
1
,
Kiyotaka Watanabe
1
,
Nobuhiko Seki
1
Affiliation
1
Division of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan.
PMID:
35116975
PMCID:
PMC8799066
DOI:
10.21037/tcr.2019.08.18
No abstract available
Publication types
Editorial
Comment